SAN FRANCISCO--(BUSINESS WIRE)--Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced that Duchesnay USA’s Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments, is now available to be prescribed via its patient access platform. It is not known if Bonjesta® is safe and effective in women with severe nausea and vomiting of pregnancy, a condition called hyperemesis gravidarum. The most common side effect of Bonjesta® is drowsiness.Phil’s customizable platform helps patients receive and refill medicines quickly, easily and affordably while giving life science companies unprecedented end-to-end visibility into the prescription life cycle
The pharmaceutical industry is one of the most highly regulated industries in the United States. Despite many legal and regulatory obstacles, the U.S. has led the world in the number of new chemical and biological entity launches since the year 2000
Editor’s Note: Digital therapeutics and other digital health technologies have significantly picked up steam in recent years as the entire healthcare ecosystem has raced to meet evolving patient demand to meet them where they are at - in their smartphones. While these technologies and platforms are a new frontier for patients, doctors, and the pharmaceutical industry, many have shown promising results at improving lives and providing additional value to key stakeholders. However, like their pharmacological counterparts, these technologies face issues of access, affordability, and adherence that often prevent patients from using them as prescribed
Editor's Note: The landmark Inflation Reduction Act has caused waves in the life sciences community as it represents the most significant piece of federal drug pricing legislation passed in decades. Key provisions outlined in the law limit drug manufacturers’ ability to raise branded list prices at rates faster than inflation and cap Medicare beneficiary out of pocket spending at $2,000 annually. The consensus among industry analysts and executives is that these measures will result in higher payer utilization management requirements, formulary rebates, and manufacturer subsidies resulting in decreased net revenue
For life science companies, patient support services have become as vital to a brand’s success as efficacy and price. A patient support services program has the potential to help break through barriers to medication access. That’s why it’s crucial to make sure it aligns with your business goals and delivers on your brand objectives while helping patients access their therapy as easily as possible
Ready to learn more?
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.